Bladder Cancer Clinical and Non-Clinical Studies, Key Companies, Therapeutic Assessment, Emerging Therapies, Treatment Algorithm, and Pipeline Analysis, DelveInsight | UroGen Pharma Ltd., Asieris Pharmaceuticals, G1 Therapeutics, Inc., LintonPharm Co.Ltd.

Bladder Cancer Pipeline constitutes 80+ key companies continuously working towards developing 100+ Bladder Cancer treatment therapies, analyzes DelveInsight.

Bladder Cancer Overview:

Bladder cancer typically begins in the cells lining the bladder and is more common in men, particularly those over 70. It is the fifth most common cancer overall and the fourth most common in men. When detected early, bladder cancer generally responds well to treatment, but it can recur years later, so ongoing monitoring is necessary. About 90% of bladder cancers are urothelial carcinoma, which remains non-muscle invasive in most cases. Less common forms of bladder cancer include squamous cell carcinoma, adenocarcinoma, and small cell carcinoma, which develop due to chronic irritation and may invade the bladder muscle over time.

The most common symptom of bladder cancer is blood in the urine, but other signs may include pain or burning during urination, frequent urination, or difficulty urinating. Advanced stages may cause lower back pain, fatigue, loss of appetite, and weight loss. Smoking is the leading risk factor for bladder cancer, with smokers being up to four times more likely to develop it. Studies show that tobacco use accounts for about 50% of bladder cancer cases.

Request for a detailed insights report on Bladder Cancer pipeline insights @ https://www.delveinsight.com/report-store/bladder-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

"Bladder Cancer Pipeline Insight 2024" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Bladder Cancer Therapeutics Market.

Key Takeaways from the Bladder Cancer Pipeline Report

DelveInsight's Bladder Cancer pipeline report depicts a robust space with 80+ active players working to develop 100+ pipeline therapies for Bladder Cancer treatment.
In February 2024, CG Oncology began the Phase III PIVOT-006 clinical trial of cretostimogene for treating intermediate-risk non-muscle invasive bladder cancer (NMIBC), with the first patient receiving treatment.
In February 2024, ImmunityBio announced that Patient-Reported Outcomes (PROs) from the Phase II/III QUILT 3.032 study of N-803 plus BCG in BCG-unresponsive NMIBC were published in the peer-reviewed journal *Urology Practice*. These PROs supported the positive interim results from the study, published in NEJM Evidence, showing that 71% of patients in cohort A with carcinoma in situ (CIS) with or without Ta/T1 disease achieved a complete response.
In February 2024, UK-based Prokarium initiated the PARADIGM-1 Phase I/Ib study in the US, dosing the first patient with ZH9, an investigational bacterial immunotherapy for NMIBC.
In January 2024, the FDA granted fast track and breakthrough therapy designations to cretostimogene grenadenorepvec (CG0070) for use in patients with high-risk, BCG-unresponsive NMIBC with carcinoma in situ, with or without Ta or T1 tumors.
In January 2024, Canadian pharmaceutical company Theralase Technologies released interim clinical data from its Phase II study of Ruvidar (TLD-1433), an intravesical photodynamic therapy for treating NMIBC.
Key Bladder Cancer companies such as UroGen Pharma Ltd., Asieris Pharmaceuticals, G1 Therapeutics, Inc., LintonPharm Co.Ltd., Vaxiion Therapeutics, Merck Sharp & Dohme LLC, CG Oncology, Inc., Ferring Pharmaceuticals, SURGE Therapeutics, Halozyme Therapeutics, ImmunityBio, Inc., AstraZeneca, Spectrum Pharmaceuticals, Inc, enGene, Inc., CicloMed LLC, Protara Therapeutics, Hoffmann-La Roche, CG Oncology, Inc., Astellas Pharma Global Development, Inc, Five Prime Therapeutics, Inc., and others are evaluating new drugs for Bladder Cancer to improve the treatment landscape.
Promising Bladder Cancer pipeline therapies in various stages of development include UGN-102, APL 1202, Trilaciclib, Catumaxomab, VAX 014, and others.

Bladder Cancer Pipeline Analysis
The report provides insights into:
The report provides detailed insights into the key companies that are developing therapies in the Bladder Cancer Market.
The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Bladder Cancer treatment.
It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Bladder Cancer market.

Download our free sample page report on Bladder Cancer pipeline insights @ https://www.delveinsight.com/sample-request/bladder-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Bladder Cancer Emerging Drugs

UGN-102: UroGen Pharma Ltd.
APL 1202 : Asieris Pharmaceuticals
Trilaciclib: G1 Therapeutics, Inc.
Catumaxomab: LintonPharm Co.,Ltd.
VAX 014: Vaxiion Therapeutics

Bladder Cancer Companies

Over 80 key companies are working on developing therapies for bladder cancer. Among them, UroGen Pharma Ltd. has drug candidates for bladder cancer in the most advanced stage, Phase III.

DelveInsight's report covers around 100+ products under different phases of clinical development like

Late stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I) along with the details of
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates

Bladder Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Intravenous
Subcutaneous
Oral
Intramuscular

Bladder Cancer Products have been categorized under various Molecule types such as

Monoclonal antibody
Small molecule
Peptide

Download Sample Pages to Get an in-depth Assessment of the Emerging Bladder Cancer Therapies and Key Companies: Bladder Cancer Clinical Trials and advancements @ https://www.delveinsight.com/report-store/bladder-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Bladder Cancer Pipeline Therapeutic Assessment
• Bladder Cancer Assessment by Product Type
• Bladder Cancer By Stage
• Bladder Cancer Assessment by Route of Administration
• Bladder Cancer Assessment by Molecule Type

Download Bladder Cancer Sample report to know in detail about the Bladder Cancer treatment market @ Bladder Cancer Therapeutic Assessment @ https://www.delveinsight.com/sample-request/bladder-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Table of Content

1. Report Introduction
2. Executive Summary
3. Bladder Cancer Current Treatment Patterns
4. Bladder Cancer - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Bladder Cancer Late-Stage Products (Phase-III)
7. Bladder Cancer Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Bladder Cancer Discontinued Products
13. Bladder Cancer Product Profiles
14. Bladder Cancer Key Companies
15. Bladder Cancer Key Products
16. Dormant and Discontinued Products
17. Bladder Cancer Unmet Needs
18. Bladder Cancer Future Perspectives
19. Bladder Cancer Analyst Review
20. Appendix
21. Report Methodology

Request the Sample PDF to Get Detailed Insights About the Bladder Cancer Pipeline Reports Offerings: https://www.delveinsight.com/report-store/bladder-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Contact Info:
Kritika Rehani
krehani@delveinsight.com
info@delveinsight.com
+14699457679

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.